MindImmune Therapeutics, Inc.

Based in Rhode Island, US, and founded in 2016 by CEO Stevin Zorn, CSO Frank Menniti, and Robert Nelson, MindImmune Therapeutics, Inc. is a medical research firm that conducts multiple programs to develop breakthrough therapeutics for Alzheimer's disease. The company's research is guided by human and animal model genetics, which leads the company to find that cells of the peripheral immune system enter and cause damage to neurons afflicted with Alzheimer’s pathology. In November 2025, MindImmune Therapeutics, Inc.

raised USD 10. 2 million in series A funding led by returning investor Dolby Family Ventures, with participation from other returning investors Pfizer Venture Investments, Slater Technology Fund. New investors Gates Frontier, The Foundation For A Better World, and other unspecified investors also participated in the round. The company is developing a novel therapeutic antibody to prevent these immune cells from entering the brain, aiming to ameliorate cognitive symptoms and slow disease progression.

MindImmune’s flagship program focuses on Alzheimer's disease, where innate immune cells are identified as infiltrating the brain and causing synaptic damage. The company will use the November 2025 funding to support advance its lead Alzheimer’s therapeutic through preclinical development and prepare for investigational new drug studies.